Mark E. Delaney, Senior Vice President and Chief Commercial Officer of Quest Diagnostics, has acquired 25 shares of the company's stock through a dividend reinvestment plan. This transaction, reported on October 23, 2026, is significant as it reflects Delaney's ongoing confidence in the company’s performance.
Quest Diagnostics is a leading provider in the medical laboratories sector, focusing on delivering accurate and timely diagnostic information. The company operates under the ticker symbol DGX and is incorporated in Delaware. Its business address is located at 500 Plaza Drive, Secaucus, NJ.
The recent filing indicates that Delaney's transaction occurred on October 21, 2026, at a price of $235.941 per share. Following this acquisition, Delaney now owns a total of 10,360 shares in the company. The filing notes that this acquisition was made under a dividend reinvestment plan, which allows shareholders to reinvest dividends to purchase additional shares.
This move may impact other executives and stakeholders within Quest Diagnostics, as such transactions can signal confidence in the company's future prospects. The medical laboratories industry is characterized by active participation from executives in share ownership, which can influence investor perceptions and market dynamics.
The filing does not specify any upcoming actions or further transactions related to this acquisition.